

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention **COMPOSITIONS AND METHODS FOR WT1 SPECIFIC
IMMUNOTHERAPY**

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☐ The attached application, or
☒ Application No. 10/002,603, filed on October 30, 2001,
☒ as amended on December 21, 2004, June 14, 2006, October 5, 2006, January 29, 2007,
May 10, 2007 (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.

All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF INVENTOR(S)

Inventor one: Alexander Gaiger Citizen of: Austria
Signature: _____ Date: _____

Inventor two: Martin A. Cheever Citizen of: US
Signature: Martin A. Cheever Date: 23 September 2009

Inventor three: _____ Citizen of: _____
Signature: _____ Date: _____

Inventor four: _____ Citizen of: _____
Signature: _____ Date: _____

Inventor five: _____ Citizen of: _____
Signature: _____ Date: _____

☐ Additional inventors or a legal representative are being named on _____ additional form(s) attached hereto.